Boston Children's Hospital
Boston, Massachusetts, 02115, United States
Location status: Recruiting
Location contact
Alissa M D'Gama, MD, PhD
PRINCIPAL_INVESTIGATOR
Beth R Sheidley, MS
CONTACT
NCT Number: NCT06701084
The goal of this study is to discover new genetic causes of infantile epilepsies and evaluate the impact of these discoveries on infants with epilepsy and their families.
Interested in participating?
Request InfoAll sexes
Interventional
Not applicable
Boston, Massachusetts, 02115, United States
Location status: Recruiting
Alissa M D'Gama, MD, PhD
PRINCIPAL_INVESTIGATOR
Beth R Sheidley, MS
CONTACT
Infantile epilepsies are common, affecting 1 in 1000 infants, and are associated with significant morbidity, mortality, healthcare costs, and caregiver burden. Although most infantile epilepsies are believed to have genetic causes, most infants with epilepsy remain genetically "unsolved" and the full genetic landscape of infantile epilepsies is unknown, which limits our ability to develop precision therapies and ultimately improve outcomes for this vulnerable population. This study aims to discover new genetic causes of infantile epilepsies and evaluate the impact of these discoveries on infants with epilepsy and their families, contributing to knowledge that will inform our scientific understanding of normal and abnormal brain development and guide clinical care and implementation of precision medicine for infants with epilepsy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Infant Criteria
Inclusion criteria
Exclusion criteria
Parent Criteria Inclusion Criteria - Parent of eligible infant (see above)
Exclusion criteria
Genomic sequencing data will be comprehensively analyzed for pathogenic variants that explain the participants epilepsy.
Time frame: Collected after return of genetic results approximately 2 weeks after infant is enrolled
The diagnostic yield of genomic sequencing will be calculated as the percentage of enrolled infants with epilepsy who receive a genetic diagnosis.
Time frame: Collected after return of genetic results approximately 2 weeks after infant is enrolled
The short-term clinical utility of genetic testing will be evaluated using the validated C-GUIDE measure. The C-GUIDE total score will be compared between infants with epilepsy who did vs did not receive a genetic diagnosis.
Time frame: Collected when infant is 2.5 years old
The parent-perceived utility of genetic testing will be evaluated using the validated GENE-U measure. The GENE-U total score will be compared between infants with epilepsy who did vs did not receive a genetic diagnosis.
Time frame: Collected when infant is 2.5 years old
Developmental progress will be evaluated using the Bayley Scales of Infant and Toddler Development Fourth Edition. The cognitive, language, and motor subscale scores will be compared between infants with epilepsy who did vs did not receive a genetic diagnosis.
Time frame: Collected at return of genetic results approximately 2 weeks after infant is enrolled and when infant is 2.5 years old
The seizure frequency will be evaluated using the seizure frequency outcome measure developed by the American Academy of Neurology and dichotomized as decrease vs no decrease between the two timepoints. The percentage of infants with this outcome will be compared between infants with epilepsy who did vs did not receive a genetic diagnosis.
Time frame: Collected when infant is 2.5 years old
This outcome will be evaluated using a qualitative approach. Semi-structured interviews will be performed with a subset of parents using purposive sampling and will be analyzed using a grounded theory iterative approach.
Contact information is provided by the study sponsor or research team.
Boston Children's Hospital
Other
Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis: Gene-Shortening Time of Evaluation in Pediatric Epilepsy Services (Gene-STEPS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.